Exelixis is an oncology-focused biotechnology company that strives to accelerate the
discovery, development, and commercialization of new medicines for
difficult-to-treat cancers. Our efforts have resulted in four approved products
available to patients worldwide. We are committed to prudently reinvesting in
our business to maximize the potential of our pipeline, through both targeted
business development and internal drug discovery – all to help cancer patients
recover stronger and live longer.